Free Delivery Over $100
|
|
|||
|
||||
OverviewThe gas nitric oxide (NO) has burst upon neuroscience only recently, and yet it has permeated into almost every avenue of current research. The unique properties of this novel messenger have revolutionized our way ofthinking about neurotransmission. These special properties have also lead neuroscientists to invoke NO to explain many previously unexplained phenomena in neurobiology. Fortunately, the development of numerous pharmacological agents is now allowing thesehypotheses to be tested.This volume will provide a synopsis of what is now known about NO. How and where NO is produced, how it acts at the molecular level to activate the synthesis of cGMP, and the possible targets of cGMP in the nervous system are reviewed. The roles of theNO/cGMP signal transduction pathway in the central and peripheral nervous systems, in glial cells, and in neuropathology are then explored. Together, these reviews will lead to further work explaining the varied functions of NO. Full Product DetailsAuthor: Peter Jenner (Emeritus Professor of Pharmacology, Institute of Pharmaceutical Sciences, King’s College London, London, UK) , Stephen R. Vincent (The University of British Columbia, Vancouver, Canada) , Peter Jenner (Division of Pharmacology and Therapeutics<br>GKT School of Biomedical Sciences<br>King's College<br>London SE1 1UL<br>United Kingdom) , Stephen R. Vincent (The University of British Columbia, Vancouver, Canada)Publisher: Elsevier Science Publishing Co Inc Imprint: Academic Press Inc Dimensions: Width: 15.20cm , Height: 2.00cm , Length: 22.90cm Weight: 0.580kg ISBN: 9780127219851ISBN 10: 0127219854 Pages: 317 Publication Date: 07 April 1995 Audience: Professional and scholarly , Professional & Vocational Format: Hardback Publisher's Status: Out of Print Availability: In Print  Limited stock is available. It will be ordered for you and shipped pending supplier's limited stock. Table of ContentsD.S. Bredt, Molecular Characterization of Nitric Oxide Synthase. B. Mayer, Biochemistry and Molecular Pharmacology of Nitric Oxide Synthases. D. Koesling, P. Humbert, and G. Schultz, The NO Receptor: Characterization and Regulation of Soluble Guanylyl Cyclase. T.M. Lincoln, Cyclic GMP Receptor Proteins: Role in Nervous System and Other Tissues. S.R. Vincent, Localization of Nitric Oxide Neurons in the Central Nervous System. P.L. Wood, NitricOxide and Excitatory Amino Acid-Coupled Signal Transduction in the Cerebellum and Hippocampus. E.M. Schuman, Nitric Oxide Signalling, Long-Term Potentiation and Long-Term Depression. S. Amir, Nitric Oxide Signaling in the Hypothalamus. S.Murphy, D.M. Grzybicki, and M.L. Simmons, Glial Cells as Nitric Oxide Sources and Targets. P.D. Varner and J.S. Beckman, Nitric Oxide Toxicity in Neuronal Injury and Degeneration. N. Toda, Nitric Oxide and the Regulation of Cerebral Arterial Tone. M.J. Rand and C.G. Li, Nitric Oxide in the Autonomic and Enteric Nervous Systems. N.O. Sjstrand and E. Klinge, Nitric Oxide and the Neural Regulation of the Penis. Chapter References. Subject Index.ReviewsAuthor InformationProfessor Peter Jenner is a specialist in preclinical aspects of neurodegenerative diseases, notably Parkinson’s disease. He has spent the major part of his career at King’s College London where he was Head of Pharmacology for 14 years before returning to his research roots and subsequently becoming Emeritus Professor of Pharmacology. Peter has expertise in drug metabolism and pharmacokinetics but neuropharmacology based on functional models of neurodegenerative diseases has formed the major focus of his work. Peter holds a BPharm, PhD and DSc degree from the University of London. He has published well over 1000 articles with more than 700 peer reviewed papers. He is a Fellow of the Royal Pharmaceutical Society, the British Pharmacological Society, the Royal Society of Medicine and of King’s College London. Peter was recently honoured with a Doctor Honoris Causa degree from Carol Davila University of Medicine and Pharmacy, Bucharest and made an Honorary Fellow of The British Pharmacological Society for his contribution to research in to movement disorders. Peter has worked closely with the pharmaceutical industry for many years and acts as an adviser and consultant to both major pharma and biotech companies. He has a wide knowledge of the drug discovery and drug development process and has been involved from molecule synthesis through to drug registration for use in man. Peter was the Founder, Director and Chief Scientific Officer of Proximagen, a biotech focussed on the treatment and cure of neurodegenerative diseases that was listed on AIMs and subsequently purchased by a US based healthcare company. He is a regular speaker at international meetings and also takes time to speak at Parkinson’s disease patient-carer groups across the UK. Tab Content 6Author Website:Countries AvailableAll regions |
||||
